Extending the benefit of lipid-regulating therapy to primary prevention.
In recent years, a number of published secondary prevention trials have further strengthened the rationale for aggressive lipid-regulating therapy in patients with established coronary artery disease. However, the role of lipid-regulating therapy in primary prevention is less well characterized. Several large primary prevention trials, using a variety of interventions, are ongoing in different populations. These include the Air Force Coronary/Texas Atherosclerosis Prevention Study, the West of Scotland Coronary Prevention Study, the Women's Health Initiative, and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. These investigations will extend the results of earlier primary prevention trials and further characterize the rationale for intervention.
Jones
P H
PH
Baylor College of Medicine, Houston, Texas, USA.
Gotto
A M
AM
D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood*; D008148:Lovastatin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use; D011322:Primary Prevention; D016032:Randomized Controlled Trials as Topic
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D008148:Lovastatin; D017035:Pravastatin